210 related articles for article (PubMed ID: 33230811)
1. The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
Kashani B; Zandi Z; Pourbagheri-Sigaroodi A; Bashash D; Ghaffari SH
J Cell Physiol; 2021 Jun; 236(6):4121-4137. PubMed ID: 33230811
[TBL] [Abstract][Full Text] [Related]
2. The role of Toll-like receptor 4 signaling pathway in ovarian, cervical, and endometrial cancers.
Lupi LA; Cucielo MS; Silveira HS; Gaiotte LB; Cesário RC; Seiva FRF; de Almeida Chuffa LG
Life Sci; 2020 Apr; 247():117435. PubMed ID: 32081661
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor 4 activation in cancer progression and therapy.
Oblak A; Jerala R
Clin Dev Immunol; 2011; 2011():609579. PubMed ID: 22110526
[TBL] [Abstract][Full Text] [Related]
4. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway.
Lucas K; Maes M
Mol Neurobiol; 2013 Aug; 48(1):190-204. PubMed ID: 23436141
[TBL] [Abstract][Full Text] [Related]
5. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer.
Mishra V; Pathak C
Int J Biol Macromol; 2019 Feb; 122():425-451. PubMed ID: 30365988
[TBL] [Abstract][Full Text] [Related]
6. Toll-Like Receptor 4 (TLR4)/Opioid Receptor Pathway Crosstalk and Impact on Opioid Analgesia, Immune Function, and Gastrointestinal Motility.
Zhang P; Yang M; Chen C; Liu L; Wei X; Zeng S
Front Immunol; 2020; 11():1455. PubMed ID: 32733481
[TBL] [Abstract][Full Text] [Related]
7. The Cancer Prevention, Anti-Inflammatory and Anti-Oxidation of Bioactive Phytochemicals Targeting the TLR4 Signaling Pathway.
Chen CY; Kao CL; Liu CM
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213077
[TBL] [Abstract][Full Text] [Related]
8. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment.
Han S; Xu W; Wang Z; Qi X; Wang Y; Ni Y; Shen H; Hu Q; Han W
Oncotarget; 2016 Jun; 7(25):37773-37789. PubMed ID: 27191981
[TBL] [Abstract][Full Text] [Related]
10. The anticancer effect of the TLR4 inhibition using TAK-242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer.
Zandi Z; Kashani B; Bashash D; Poursani EM; Mousavi SA; Chahardoli B; Ghaffari SH
J Cell Biochem; 2020 Feb; 121(2):1623-1634. PubMed ID: 31535397
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptors Signaling in the Tumor Microenvironment.
McCall KD; Muccioli M; Benencia F
Adv Exp Med Biol; 2020; 1223():81-97. PubMed ID: 32030686
[TBL] [Abstract][Full Text] [Related]
12. Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling.
Klett J; Reeves J; Oberhauser N; Pérez-Regidor L; Martín-Santamaria S
Curr Top Med Chem; 2014; 14(23):2672-83. PubMed ID: 25515751
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
14. TLR4 signaling: a potential therapeutic target in ischemic coronary artery disease.
Jia SJ; Niu PP; Cong JZ; Zhang BK; Zhao M
Int Immunopharmacol; 2014 Nov; 23(1):54-9. PubMed ID: 25158302
[TBL] [Abstract][Full Text] [Related]
15. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.
Ou T; Lilly M; Jiang W
Front Immunol; 2018; 9():1188. PubMed ID: 29928275
[TBL] [Abstract][Full Text] [Related]
16. Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview.
Romerio A; Peri F
Front Immunol; 2020; 11():1210. PubMed ID: 32765484
[TBL] [Abstract][Full Text] [Related]
17. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
18. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
19. Insight Into TLR4-Mediated Immunomodulation in Normal Pregnancy and Related Disorders.
Firmal P; Shah VK; Chattopadhyay S
Front Immunol; 2020; 11():807. PubMed ID: 32508811
[TBL] [Abstract][Full Text] [Related]
20. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.
Nasser MW; Elbaz M; Ahirwar DK; Ganju RK
Cancer Lett; 2015 Aug; 365(1):11-22. PubMed ID: 25963887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
